A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505 to Treat Hyperphosphatemia in Hemodialysis Patients
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
A multi-center, open-label, parallel-design, active-controlled phase 2 study to evaluate the
tolerability, safety and efficacy of various dosages of VS-505 compared with Sevelamer
Carbonate when given orally with meal for 6 weeks to treat hyperphosphatemia in chronic
kidney disease subjects receiving maintenance hemodialysis.